Cytokinetics (CYTK) announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic ...
New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with Disopyramideand ...